Find Florida

Wednesday, September 28, 2016

Trental

Trental is a brand name of pentoxifylline, approved by the FDA in the following formulation(s):

TRENTAL (pentoxifylline - tablet, extended release; oral)

Manufacturer: SANOFI AVENTIS US

Approval date: August 30, 1984

Strength(s): 400MG ^[RLD]^[AB]

Has a generic version of Trental been approved?

Yes. The following products are equivalent to Trental:

pentoxifylline tablet, extended release; oral

Manufacturer: APOTEX

Approval date: June 9, 1999

Strength(s): 400MG ^[AB]

Manufacturer: IMPAX LABS

Approval date: August 10, 1999

Strength(s): 400MG ^[AB]

Manufacturer: MYLAN

Approval date: July 8, 1997

Strength(s): 400MG ^[AB]

Manufacturer: PLIVA

Approval date: May 25, 1999

Strength(s): 400MG ^[AB]

Manufacturer: VALEANT INTL

Approval date: July 20, 1998

Strength(s): 400MG ^[AB]

Manufacturer: WATSON LABS

Approval date: September 4, 1998

Strength(s): 400MG ^[AB]

PENTOXIL (pentoxifylline tablet, extended release; oral)

Manufacturer: UPSHER SMITH

Approval date: March 31, 1999

Strength(s): 400MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trental. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Trental.

Has a generic version of Tradjenta been approved?

No. There is currently no therapeutically equivalent version of Tradjenta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tradjenta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Patent 6,303,661
Issued: October 16, 2001
Inventor(s): Demuth; Hans-Ulrich & Rosche; Fred & Schmidt; Joem & Pauly; Robert P. & McIntosh; Christopher H. S. & Pederson; Ray A.
Assignee(s): Probiodrug
Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.
Patent expiration dates:
- April 24, 2017
  ✓
  Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR

Method of regulating glucose metabolism, and reagents related thereto
Patent 6,890,898
Issued: May 10, 2005
Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
Assignee(s): Trustees of Tufts College
1149336 Ontario Inc.
New England Medical Center Hospitals, Inc.
The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.
Patent expiration dates:
- February 2, 2019
  ✓
  Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS

Method of regulating glucose metabolism, and reagents related thereto
Patent 7,078,381
Issued: July 18, 2006
Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
Assignee(s): Trustees of Tufts College
The present invention provides methods and compositions for modifying glucose metabolism and treating Type II diabetes in an animal, along with modifying metabolism of a peptide hormone in an animal. Compositions disclosed herein comprise one or more peptides and/or peptide analogs which include a functional group that reacts with an active site residue of a protease.
Patent expiration dates:
- February 2, 2019
  ✓
  Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Patent 7,407,955
Issued: August 5, 2008
Inventor(s): Himmelsbach; Frank & Langkopf; Elke & Eckhardt; Matthias & Mark; Michael & Maier; Roland & Lotz; Ralf R. H. & Tadayyon; Mohammad
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co., KG
The present invention relates to substituted xanthines of general formula wherein R1 to R3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
Patent expiration dates:
- August 12, 2023
  ✓
  Drug substance
  ✓
  Drug product

Method of regulating glucose metabolism, and reagents related thereto
Patent 7,459,428
Issued: December 2, 2008
Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
Assignee(s): Trustees of Tufts College
New England Medical Center Hospitals, Inc.
1149336 Ontario, Inc.
One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal.
Patent expiration dates:
- February 2, 2019
  ✓
  Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- May 2, 2016 - NEW CHEMICAL ENTITY

Has a generic version of Vimovo been approved?

No. There is currently no therapeutically equivalent version of Vimovo available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vimovo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Compositions
Patent 5,714,504
Issued: February 3, 1998
Inventor(s): Lindberg; Per Lennart & Von Unge; Sverker
Assignee(s): Astra Aktiebolag
The novel optically pure compounds Na.sup.+, Mg.sup.2+, Li.sup.+, K.sup.+, Ca.sup.2+ and N.sup.+ (R).sub.4 salts of (+)-5-methoxy-2-››(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl!sulfinyl!-1H- benzimidazole or (-)-5-methoxy-2-››(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl!sulfinyl!-1H- benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.
Patent expiration dates:
- February 3, 2015
  ✓
  Patent use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
  ✓
  Drug product
- August 3, 2015
  ✓
  Pediatric exclusivity

Omeprazole magnesium salt form
Patent 5,900,424
Issued: May 4, 1999
Inventor(s): Kallstrom; Lars .ANG.ke & Nygren; Monica Annelie
Assignee(s): Astra Aktiebolag
A novel compound form of magnesium omeprazole useful in the manufacture of pharmaceutical formulations, the use of the product and the process for its production are described.
Patent expiration dates:
- May 4, 2016
  ✓
  Patent use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
  ✓
  Drug substance
- November 4, 2016
  ✓
  Pediatric exclusivity

Form of S-omeprazole
Patent 6,369,085
Issued: April 9, 2002
Inventor(s): Hanna; Cotton & Anders; Kronström & Anders; Mattson & Eva; Möller
Assignee(s): AstraZeneca AB
The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
Patent expiration dates:
- May 25, 2018
  ✓
  Patent use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
  ✓
  Drug substance
  ✓
  Drug product
- November 25, 2018
  ✓
  Pediatric exclusivity

Compounds
Patent 6,875,872
Issued: April 5, 2005
Inventor(s): Lindberg; Per Lennart & Von Unge; Sverker
Assignee(s): AstraZeneca
The novel optically pure compounds Na+, Mg2+, Li+, K+, Ca2+ and N+(R)4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.
Patent expiration dates:
- May 27, 2014
  ✓
  Drug substance
- November 27, 2014
  ✓
  Pediatric exclusivity

Pharmaceutical compositions for the coordinated delivery of NSAIDs
Patent 6,926,907
Issued: August 9, 2005
Inventor(s): Plachetka; John R.
Assignee(s): Pozen Inc.
The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
Patent expiration dates:
- February 28, 2023
  ✓
  Patent use: RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
  ✓
  Drug product

Form of S-omeprazole
Patent 7,411,070
Issued: August 12, 2008
Inventor(s): Cotton; Hanna & Kronström; Anders & Mattson; Anders & Möller; Eva
Assignee(s): AstraZeneca AB
The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
Patent expiration dates:
- May 25, 2018
  ✓
  Patent use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
  ✓
  Drug substance
- November 25, 2018
  ✓
  Pediatric exclusivity

Form of S-omeprazole
Patent 7,745,466
Issued: June 29, 2010
Inventor(s): Cotton; Hanna & Kronström; Anders & Mattson; Anders & Möller; Eva
Assignee(s): AstraZeneca AB
The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
Patent expiration dates:
- October 13, 2018
  ✓
  Patent use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- April 30, 2013 - NEW COMBINATION

Has a generic version of Viramune been approved?

No. There is currently no therapeutically equivalent version of Viramune available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Viramune. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
Patent 5,366,972
Issued: November 22, 1994
Inventor(s): Hargrave; Karl D. & Proudfoot; John R. & Adams; Julian & Grozinger; Karl G. & Schmidt, deceased; Gunther & Engel; Wolfhard & Trummlitz; Gunther & Eberlein; Wolfgang
Assignee(s): Boehringer Ingelheim Pharmaceuticals, Inc.
Disclosed are novel 5,11-dihydro-6H-dipyrido[3,2-b; 2',3'-e][1,4]diazepines. These are useful in the prevention or treatment of HIV infection.
Patent expiration dates:
- November 22, 2011
  ✓
  Patent use: METHOD FOR TREATING HIV-1 INFECTION
- November 22, 2011
- May 22, 2012
  ✓
  Pediatric exclusivity

Has a generic version of Promacta been approved?

No. There is currently no therapeutically equivalent version of Promacta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Promacta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Metal complexes
Patent 6,280,959
Issued: August 28, 2001
Inventor(s): Gleason; John G. & Luengo; Juan I.
Assignee(s): SmithKline Beecham Corporation
The invention describes zinc chelated dimeric cell-surface receptor ligands, pharmaceutical compositions containing these compounds, methods of using these compounds as agonist of dimeric cell-surface receptors. Novel processes used in preparing the compounds are also described. Further, the invention describes novel receptor binding moieties of the zinc chelated cell-surface receptor ligands.
Patent expiration dates:
- October 30, 2018
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
  ✓
  Drug substance
  ✓
  Drug product

Thrombopoietin mimetics
Patent 7,160,870
Issued: January 9, 2007
Inventor(s): Duffy; Kevin J. & Erickson-Miller; Connie & Jenkins; Julian & Luengo; Juan I. & Visonneau; Sophie
Assignee(s): SmithKline Beecham Corporation
Glaxo Group Limited
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Patent expiration dates:
- December 8, 2021
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
  ✓
  Drug substance
  ✓
  Drug product

Thrombopoietin mimetics
Patent 7,332,481
Issued: February 19, 2008
Inventor(s): Duffy; Kevin J. & Erickson-Miller; Connie & Jenkins; Julian & Luengo; Juan & Price; Alan T. & Shaw; Antony N. & Visonneau; Sophie & Wiggall; Kenneth
Assignee(s): SmithKline Beecham Corporation
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Patent expiration dates:
- May 24, 2021
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

Thrombopoietin mimetics
Patent 7,452,874
Issued: November 18, 2008
Inventor(s): Duffy; Kevin J. & Luengo; Juan I. & Shaw; Antony N. & Wiggall; Kenneth
Assignee(s): SmithKline Beecham Corp.
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Patent expiration dates:
- May 24, 2021
  ✓
  Drug substance
  ✓
  Drug product

Thrombopoietin mimetics
Patent 7,473,686
Issued: January 6, 2009
Inventor(s): Duffy; Kevin J. & Erickson-Miller; Connie & Jenkins; Julian & Luengo; Juan I. & Visonneau; Sophie
Assignee(s): SmithKline Beecham Corp.
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Patent expiration dates:
- May 24, 2021
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
  ✓
  Drug substance
  ✓
  Drug product

3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Patent 7,547,719
Issued: June 16, 2009
Inventor(s): Moore; Stephen
Assignee(s): SmithKline Beecham Corp.
An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid.
Patent expiration dates:
- July 13, 2025
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
  ✓
  Drug substance
  ✓
  Drug product

Thrombopoietin mimetics
Patent 7,790,704
Issued: September 7, 2010
Inventor(s): Duffy; Kevin J. & Erickson-Miller; Connie & Jenkins; Julian & Luengo; Juan I.
Assignee(s): GlaxoSmithKline, LLC
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Patent expiration dates:
- May 24, 2021
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Patent 7,795,293
Issued: September 14, 2010
Inventor(s): Moore; Stephen
Assignee(s): GlaxoSmithKline LLC
An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid.
Patent expiration dates:
- May 21, 2023
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Patent 8,052,993
Issued: November 8, 2011
Inventor(s): Muller; Francis X & Kapsi; Shivakumar G
Assignee(s): GlaxoSmithKline LLC
Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl) -1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
Patent expiration dates:
- August 1, 2027
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
  ✓
  Drug product

3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Patent 8,052,994
Issued: November 8, 2011
Inventor(s): Muller; Francis X. & Kapsi; Shivakumar G.
Assignee(s): GlaxoSmithKline LLC
Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
Patent expiration dates:
- August 1, 2027
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
  ✓
  Drug product

3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Patent 8,062,665
Issued: November 22, 2011
Inventor(s): Muller; Francis X & Kapsi; Shivakumar G
Assignee(s): GlaxoSmithKline LLC
Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
Patent expiration dates:
- August 1, 2027
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
  ✓
  Drug product

3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Patent 8,071,129
Issued: December 6, 2011
Inventor(s): Muller; Francis X & Kapsi; Shivakumar G
Assignee(s): GlaxoSmithKline LLC
Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl) -1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
Patent expiration dates:
- August 1, 2027
  ✓
  Patent use: TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- November 20, 2013 - NEW CHEMICAL ENTITY
- November 20, 2015 - ORPHAN DRUG EXCLUSIVITY

Tuesday, September 27, 2016

Viagra

Viagra is a brand name of sildenafil, approved by the FDA in the following formulation(s):

VIAGRA (sildenafil citrate - tablet; oral)

Manufacturer: PFIZER IRELAND

Approval date: March 27, 1998

Strength(s): EQ 100MG BASE ^[RLD], EQ 25MG BASE, EQ 50MG BASE

Has a generic version of Viagra been approved?

No. There is currently no therapeutically equivalent version of Viagra available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Viagra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Pyrazolopyrimidinone antianginal agents
Patent 5,250,534
Issued: October 5, 1993
Inventor(s): Bell; Andrew S. & Brown; David & Terrett; Nicholas K.
Assignee(s): Pfizer Inc.
Compounds of the formula: ##STR1## wherein R.sup.1 is H, C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.5 cycloalkyl or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.2 is H, C.sub.1 -C.sub.6 alkyl optionally substituted by OH, C.sub.1 -C.sub.3 alkoxy or C.sub.3 -C.sub.6 cycloalkyl, or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.3 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 alkenyl, C.sub.3 -C.sub.6 alkynyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.6 perfluoroalkyl or (C.sub.3 -C.sub.6 cycloalkyl)C.sub.1 -C.sub.6 alkyl; R.sup.4 taken together with the nitrogen atom to which it is attached completes a pyrrolidinyl, piperidino, morpholino, or 4-N-(R.sup.6)-piperazinyl group; R.sup.5 is H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.3 alkoxy, NR.sup.7 R.sup.8, or CONR.sup.7 R.sup.8 ; R.sup.6 is H, C.sub.1 -C.sub.6 alkyl, (C.sub.1 -C.sub.3 alkoxy) C.sub.2 - C.sub.6 alkyl, hydroxy C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 N)C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 NCO)C.sub.1 -C.sub.6 alkyl, CONR.sup.7 R.sup.8, CSNR.sup.7 R.sup.8 or C(NH)NR.sup.7 R.sup.8 ; R.sup.7 and R.sup.8 are each independently H, C.sub.1 -C.sub.4 alkyl, (C.sub.1 -C.sub.3 alkoxy)C.sub.2 -C.sub.4 alkyl or hydroxy C.sub.2 -C.sub.4 alkyl; and pharmaceutically acceptable salts thereof, are selective cGMP PDE inhibitors useful in the treatment of cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.
Patent expiration dates:
- March 27, 2012
- September 27, 2012
  ✓
  Pediatric exclusivity

Pyrazolopyrimidinones for the treatment of impotence
Patent 6,469,012
Issued: October 22, 2002
Inventor(s): Peter; Ellis & Nicholas Kenneth; Terrett
Assignee(s): Pfizer Inc
The use of a compound of formula (I) wherein R1 is H; C1-C3 alkyl; C1-C3 perfluoroalkyl; or C3-C5 cycloalkyl; R2 is H; optionally substituted C1-C6 alkyl; C1-C3 perfluoroalkyl; or C3-C6 cycloalkyl; R3 is optionally substituted C1-C6 alkyl; C1-C6 perfluoroalkyl; C3-C5 cycloalkyl; C3-C6 alkenyl; or C3-C6 alkynyl; R4 is optionally substituted C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkanoyl, (hydroxy)C2-C4 alkyl or (C2-C3 alkoxy)C1-C2 alkyl; CONR5R6; CO2R7; halo; NR5R6; NHSO2NR5R6; NHSO2R8; SO2NR9R10; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl; R5 and R6 are each independently H or C1-C4 alkyl, or together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino, 4-N(R11)-piperazinyl or imidazolyl group; R7 is H or C1-C4 alkyl; R8 is optionally substituted C1-C3 alkyl; R9 and R10 together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino or 4-N(R12)-piperazinyl group; R11 is H; optionally substituted C1-C3 alkyl; (hydroxy)C2-C3 alkyl; or C1-C4 alkanoyl; R12 is H; optionally substituted C1-C6 alkyl; CONR13R14; CSNR13R14; or C(NH)NR13R14; and R&quest;13&quest; and R14 are each independently H; C1-C4 alkyl; or substituted C2-C4 alkyl; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man; a pharmaceutical composition for said treatment; and a method of said treatment of said male animal with said pharmaceutical composition or with said either entity.
Patent expiration dates:
- October 22, 2019
  ✓
  Patent use: TREATMENT OF ERECTILE DYSFUNCTION
- April 22, 2020
  ✓
  Pediatric exclusivity

Has a generic version of Arestin been approved?

No. There is currently no therapeutically equivalent version of Arestin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Arestin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Arestin.

Wednesday, September 28, 2016

Trental

TRENTAL (pentoxifylline - tablet, extended release; oral)

Has a generic version of Trental been approved?

pentoxifylline tablet, extended release; oral

PENTOXIL (pentoxifylline tablet, extended release; oral)

Related Patents

See also...

Tradjenta

TRADJENTA (linagliptin - tablet; oral)

Has a generic version of Tradjenta been approved?

Related Patents

Related Exclusivities

See also...

Vimovo

VIMOVO (esomeprazole magnesium; naproxen - tablet, delayed release; oral)

Has a generic version of Vimovo been approved?

Related Patents

Related Exclusivities

See also...

Viramune

VIRAMUNE (nevirapine - suspension; oral)

VIRAMUNE (nevirapine - tablet; oral)

Has a generic version of Viramune been approved?

Related Patents

See also...

Promacta

PROMACTA (eltrombopag olamine - tablet; oral)

Has a generic version of Promacta been approved?

Related Patents

Related Exclusivities

See also...

Tuesday, September 27, 2016

Viagra

VIAGRA (sildenafil citrate - tablet; oral)

Has a generic version of Viagra been approved?

Related Patents

See also...

Arestin

ARESTIN (minocycline hydrochloride - powder, extended release; dental)

Has a generic version of Arestin been approved?

Related Patents

See also...